NDAINTRAVENOUSSOLUTION
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLYRCADO (flurpiridaz f-18) by Bayer is positron emitting activity [moa]. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLYRCADO (flurpiridaz F-18) is a radioactive diagnostic agent administered intravenously that uses positron-emitting activity to enable cardiac PET imaging. It is indicated for myocardial perfusion imaging in patients with suspected or known coronary artery disease. The drug works by localizing in viable myocardium, allowing clinicians to visualize regional blood flow and cardiac viability.
Growth15.5 years to LOE
As a newly approved growth-stage diagnostic agent with no current competition, the Bayer commercial team is building market infrastructure and establishing cardiac imaging protocols, indicating active hiring and team expansion.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLYRCADO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.